Located in Toronto, Palo Alto, and New York City, Xtreme Labs leads the world's biggest brands in creating award-winning mobile products. Xtreme Labs' expertise in mobile spans both the consumer and enterprise industries, providing a wide range of solutions for mobile, tablet, TV, mobile web, connected devices and more. All projects are handled in-house by a talented team of engineers, designers, product managers, QA and U/X experts.   For more information visit http://www.xtremelabs.com.

Xtreme Labs

Social Capital is a Menlo Park-based investment firm whose mission is to advance humanity by solving the world’s hardest problems. By harnessing technology to address core human needs, they aim to drive a bottom-up redistribution of power, capital and opportunity. To achieve this, they're building a new kind of company and a platform for empowering brilliant entrepreneurs and breakthrough products. Founded in 2011, the company is based in Menlo Park, California, United States.

Social Capital

Intuit offers business and financial management solutions for SMBs, financial institutions, consumers, and accounting professionals. The company’s product portfolio includes TurboTax, a software solution that offers free tax filing, file taxes, and income tax returns; Quicken; QuickBooks; Mint.com, and m

Intuit

Glooko develops a remote patient-monitoring platform to identify at-risk patients with diabetes. It integrates with diabetes devices, fitness wearables, and activity trackers to allow data capture and provide reports and analytics that aim to drive behavior change and outcomes. The platform not only syncs diabetes data but also enhances communication between individuals with diabetes and their healthcare providers, leading to improved health outcomes. Glooko is available on both Android and iOS, providing users with the ability to track their diabetes data on their smartphones.

Glooko

Samsung NEXT Ventures is an investment arm of Samsung NEXT, a multifaceted innovation group within Samsung Electronics dedicated to identifying new growth opportunities that will define the next decade. The firm prefers to invest in artificial intelligence, fintech, blockchain, health technology, infrastructure, and media technology sectors.

Samsung NEXT

Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud, marketplaces, frontier tech, biopharma, digital health, and medtech.

Canaan Partners

Medtronic provides healthcare technology solutions for complex and challenging conditions. They deliver treatments and therapies for the lungs, brain, dental, diabetes, ENT, heart, gastrointestinal, orthopedic, urinary, and women's health. The company's technologies and therapies treat 70 different medical conditions and include patient monitoring systems, robotic surgery, insulin pumps, cardiac devices, and more. Medtronic delivers innovative technologies that change people's lives through to its extensive knowledge, insatiable curiosity, and desire to assist everyone in need.

Medtronic

Georgian is a fintech company that invests in high growth software companies that harness the power of data in a trustworthy way. They're building a platform to provide a better experience of growth capital to software company CEOs and their teams.  Georgian's platform is designed to identify and accelerate the best growth-stage software companies, taking an intelligent, data-first approach to solving the key challenges CEOs face as they grow their businesses. They invest in companies across North America that harness the power of data in a trustworthy way. Based in Toronto and founded in 2008, Georgian’s team brings together software entrepreneurs, machine learning experts, experienced operators, and investment professionals.

Georgian

Insulet Corporation, a medical device company, engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes primarily in the United States. The company offers OmniPod Insulin Management System (OmniPod System), an insulin infusion system that provides a pain-free automated cannula insertion. The OmniPod System consists of OmniPod disposable insulin infusion device and handheld wireless personal diabetes manager; and provides people with a diabetes management solution that offers lifestyle and other benefits. The company sells the OmniPod System directly to patients through referrals from healthcare professionals and through patient leads.   Insulet Corporation was founded in 2000 and is headquartered in Bedford, Massachusetts.

Insulet

Mayo Clinic, a not-for-profit medical group practice, provides medical care, research, and education services. It offers medical care services in various specialties, including diabetes and endocrinology, gastroenterology, gynecology, cancer, neurology and neurosurgery, orthopedics, pulmonology, rheumatology, nephrology, urology, and cardiology and heart surgery.

Mayo Clinic

Health Catalyst Capital Management is a venture capital fund investing in high growth US- based Healthcare IT businesses focused in a few key themes, each with potential to achieve $1 billion enterprise value in new or disrupted markets globally.

Health Catalyst Capital

Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases. Its main offerings include pioneering scientific breakthroughs and expanding access to their medicines, with the ultimate goal of preventing and curing disease.

Novo Nordisk

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

Glooko is an app-based remote patient monitoring and diabetes management platform that collects patient data from a range of third-party glucose monitoring devices. The company’s technology integrates with over 200 diabetes and biometric devices worldwide, offering the largest compatibility among connected care platforms.Glooko’s FDA-approved Mobile Insulin Dose Adjustment System (MIDS) allows healthcare providers to create customized care plans and provides patients with daily instructions on recommended insulin dosage levels based on the readings from the glucose monitoring devices. The platform also allows diabetic patients to track activity data and meals, access educational material, and follow care plans that are monitored through the app.In <a href="https://sp-edge.com/updates/9200?industryIds=22">March 2022</a>, Glooko acquired Paris-based DIABNEXT, a diabetes care platform, and rebranded it as Glooko XT for the French market. Furthermore, in <a href="https://sp-edge.com/updates/8154">January 2022</a>, Glooko acquired Berlin-based xbird, a medical AI company developing solutions for predicting health risks and supporting diabetes management through personalized interventions.Key customers and partnershipsAs of October 2024, Glooko had partnered with more than 8,000 clinics and served 4.4 million users with diabetes across 30 countries.&nbsp;The company has established several key partners, including 1) <a href="https://www.hedia.com/hedia-and-glooko-reveal-new-global-partnership/">Hedia</a> to integrate Hedia's insulin dosing algorithm into Glooko's platforms (June 2023), 2) <a href="https://sp-edge.com/updates/25233">Better Therapeutics</a> to integrate Better Therapeutics' AspyreRx into Glooko's platform (January 2024), and 3) Sanofi to integrate Sanofi's SoloSmart device into the Glooko platform (February 2023).

More important now than ever, telehealth will long outlast the pandemic that drove its growth.

Telehealth

Glooko is an app-based remote patient monitoring and diabetes management platform that collects patient data from a range of third-party glucose monitoring devices. Glooko’s US Food &amp; Drug Administration approved Mobile Insulin Dose Adjustment System (MIDS) allows healthcare providers to create customized care plans and provides patients with daily instructions on recommended insulin dosage levels based on the readings from the glucose monitoring devices.The platform also allows diabetic patients to track activity data and meals, access educational material, and follow care plans that are monitored through the app. As of March 2021, the app has partnered with more than 7,500 clinics and served 3 million users with diabetes across 27 countries.As of March 2022, the company had acquired two companies: 1) <a href="https://sp-edge.com/updates/8154">xbird </a>, a German AI-backed medical company, and 2) French diabetes care platform <a href="https://sp-edge.com/updates/9200?industryIds=22">DIABNEXT </a>as part of its planned global expansion drive. The integration of xbird’s Just In Time Adaptive Intervention technology will enhance Glooko’s advanced analytics capabilities and tools as well as expand its global reach across 7,500 clinics and more than one million users. DIABNEXT will be rebranded as Glooko XT and two platforms will be available for the French market which allow the company to scale its operations into more regions and expand its remote patient monitoring services.As of <a href="https://sp-edge.com/updates/34688">October 2024</a>, more than 4.4 million people worldwide with diabetes have used the Glooko platform.

Glooko is an app-based remote patient monitoring and diabetes management platform that collects patient data from a range of third-party glucose monitoring devices. Glooko’s US Food &amp; Drug Administration approved Mobile Insulin Dose Adjustment System (MIDS) allows healthcare providers to create customized care plans and provides patients with daily instructions on recommended insulin dosage levels based on the readings from the glucose monitoring devices.

Glooko is an app-based remote patient monitoring and diabetes management platform that collects patient data from a range of third-party glucose monitoring devices. The company’s technology integrates with over 200 diabetes and biometric devices worldwide, offering the largest compatibility among connected care platforms.

Glooko collects $100M, plus a new CEO, to boost its diabetes platform

Terumo Corporation

This new integration will enable people with diabetes to transfer recorded data from MEDISAFE WITHTM insulin patch pump into the Glooko platform, thus helping them to visualize insulin dosage, food, and activities in graphs more easily and to realize personalized remote patient monitoring and patient care more effectively.

Platforms offer a subscription-based or B2B-sponsored, evidence-based program for managing a specific long-term health condition.

Eli Lilly

Eli Lilly (LLY) forges strategic global partnerships with Glooko, DexCom, myDiabby Healthcare, and Roche to enhance diabetes management. These alliances aim to integrate Lilly's Tempo Pen™ and pending Tempo Smart Button™ with diverse diabetes management platforms, enabling personalized data integration and insights for individuals with diabetes

The partnership will enable the integration of data from Terumo's diabetes care devices such as MEDISAFE WITHTM insulin patch pump and MEDISAFE Fit SmileTM blood glucose meters into Glooko's diasend® diabetes data management platform.

Glooko is an app-based remote patient monitoring and diabetes management platform that collects patient data from a range of third-party glucose monitoring devices. Glooko’s US Food &amp; Drug Administration approved Mobile Insulin Dose Adjustment System (MIDS) allows healthcare providers to create customized care plans and provides patients with daily instructions on recommended insulin dosage levels based on the readings from the glucose monitoring devices.The platform also allows diabetic patients to track activity data and meals, access educational material, and follow care plans that are monitored through the app. As of March 2021, the app has partnered with more than 7,500 clinics and served 3 million users with diabetes across 27 countries.&nbsp;As of March 2022, the company had acquired two companies: 1) <a href="https://sp-edge.com/updates/8154">xbird </a>, a German AI-backed medical company, and 2) French diabetes care platform <a href="https://sp-edge.com/updates/9200?industryIds=22">DIABNEXT </a>as part of its planned global expansion drive. The integration of xbird’s Just In Time Adaptive Intervention technology will enhance Glooko’s advanced analytics capabilities and tools as well as expand its global reach across 7,500 clinics and more than one million users. DIABNEXT will be rebranded as Glooko XT and two platforms will be available for the French market which will allow the company to scale its operations into more regions and expand its remote patient monitoring services.Key customers and partnershipsIn <a href="https://sp-edge.com/updates/25233">January 2024</a>, the company partnered with Better Therapeutics to integrat Better Therapeutics' recently launched AspyreRx , a digital behavioral treatment for type 2 diabetes (T2D), into Glooko's platform.Funding and financials&nbsp;In March 2021, the company concluded a Series D round that brought its total funding up to USD 101 million to enter new geographical locations and expand its clinical product offerings to cover other chronic diseases.

Cardiomo Care is developing noninvasive wearable devices to alert users and caretakers when there are abnormalities in the heartbeat. The company’s AI engine, trained on existing and growing data sets, can predict potential heart issues up to two hours before they occur, enabling early detection and intervention for arrhythmias and other cardiovascular diseases (CVDs).The company's product, CardiomoPatch, is a waterproof, wearable patch capable of long-term wear with a 10-day battery life. The patch monitors a patient's cardiac data, including ECG outputs, breathing, and skin temperature, and transmits the data via a mobile app for analysis by Cardiomo's AI engine.&nbsp;As of May 2024, the company is yet to commercialize its product and has over 1,600 pre-orders.

Cardiomo Care

Omada is a prevention-focused digital therapeutics startup that helps members achieve health goals through lifestyle changes. It offers four evidence-based, virtual prevention programs for managing hypertension, musculoskeletal (MSK) issues, prediabetes, and diabetes.Omada offers real-time data tracking through connected devices (such as wireless scales, blood pressure, and glucose monitors) and access to personalized coaching sessions via a mobile app as part of its prevention program. It also provides an online community of peers with similar health conditions to discuss challenges and provide support. In May 2021, Omada became the first fully-virtual healthcare provider to earn the National Committee for Quality Assurance’s Population Health Program Accreditation for its type 2 diabetes and type 2 diabetes + hypertension programs.Unlike its peers, Omada operates a performance-based business model where it charges clients an enrollment fee based on the number of users and a performance fee based on how much weight their employees lose. In May 2020, the company acquired virtual physical therapy startup Physera.Key customers and partnershipsAs of May 2024, Omada had more than 1 million members from more than 1,900 enterprise clients across all 50 US states. Its B2B employer and health plan client base include key clients such as American Eagle, Kaiser Permanente, Costco Wholesale, 3M, and Marvin. Additionally, the company has partnered with health systems and hospitals such as Intermountain Healthcare to provide its preventive programs as a covered benefit.In <a href="https://sp-edge.com/updates/15587">January 2023</a>, the company partnered with health service company Castell (a subsidiary of Intermountain Healthcare) to provide its diabetes programs to members from Intermountain Healthcare’s primary care providers in its Utah Medical Group. Further in <a href="https://sp-edge.com/updates/25245">January 2024</a>, the company partnered with Amazon to expand access to its cardiometabolic program.

Omada Health

VillageMD provides primary care services for patients. It also provides tools, technology, and staffing support needed for physicians to deliver high-quality services. VillageMD’s service delivery methods include traditional freestanding clinics, Village Medical at Walgreens co-located clinics, as well as at-home and around-the-clock virtual visits. It also leverages a team-based approach to care where physicians lead nurse practitioners, pharmacists, mental health specialists, and dietitians to offer a holistic care program. The technology of VillageMD includes docOS, an operating system that enables better patient care by connecting various clinical source systems with ongoing patient-generated data coupled with an AI engine to continuously analyze messages to enable patient self-care.The company made several acquisitions to expand its footprint: 1) <a href="https://sp-edge.com/updates/14347">Summit Health</a> for USD 8.9 billion in November 2022, 2) Healthy Interactions, an interactive patient education platform, in February 2022, and 3) <a href="https://sp-edge.com/updates/16968">Starling Physicians</a>, a primary care and specialty care provider, in March 2023.Key customers and partnershipsIn June 2020, VillageMD and Walgreens Boots Alliance announced a collaborative effort to open at least 600 Village Medical centers at Walgreens across more than 30 US markets by 2025. Walgreens invested USD 5.2 billion in VillageMD (from the previously announced USD 1.0 billion), raising its ownership stake to 63% (from 30%).However, as of May 2024, Walgreens had plans to close 160 VillageMD clinics as part of a cost-cutting plan.

VillageMD

Cityblock Health is a value-based healthcare provider focused on delivering comprehensive care to underserved communities, primarily Medicaid and lower-income Medicare beneficiaries. The company combines primary care, behavioral health, and social services to address the complex physical, mental, and social needs of its members.Cityblock's model involves partnering with local community-based organizations and deploying multidisciplinary care teams that include doctors, nurses, behavioral health specialists, and community health workers. These teams provide personalized care through 24/7 access to multi-modal care delivery, including in-home visits, telehealth, and community health hubs.The services of Cityblock are available to members at no additional cost if they are covered by an eligible health plan.Key Customers and PartnershipsAs of May 2024, the company’s services were available in seven states across the US and served over 100,000 members.In May 2024, it partnered with <a href="https://sp-edge.com/updates/29647">Sunshine Health</a> to expand to Florida, and, in <a href="https://sp-edge.com/updates/13270">September 2022</a>, it partnered with MDwise to expand into Indiana. Prior to that, the company had partnered with insurance providers such as ConnectiCare (Connecticut), Tufts Health Plan (Massachusetts), Emblem Health (New York), Healthy Blue (North Carolina), Molina Healthcare (Ohio) and CareFirst (Washington DC).Funding and FinancialsCityblock is a spin-off of Sidewalk Labs, an Alphabet company that incubates and invests in tech companies and products to improve urban infrastructure. It completed a USD 400 million Series D funding round led by Softbank in <a href="https://sp-edge.com/updates/5326">September 2021</a>, valuing the company at USD 5.7 billion. The funds were used to expand its services.

Cityblock Health

Everside Health (formerly Paladina Health) offers preventative care for chronic conditions and primary, mental and occupational healthcare treatments for acute conditions. Patients benefit from around-the-clock access to care, same-day or next-day appointments for in-person, and virtual care visits with zero copays.Everside aims to generate around 17% healthcare cost savings in three years and 31% in five years for its corporate members by leveraging a data-driven approach to care coordination.The company leverages data from past medical records, predictive analytics, and AI in the delivery of preventative care services.Founded in 2010 under the name Paladina Health, the company was rebranded in November 2020 as Everside Health following a merger between three primary care groups (Paladina, Activate Healthcare, and Healthstat). Furthermore, in February 2024, Everside Health merged with primary care provider Marathon Health to form a combined entity that would operate as Marathon Health, and, as of May 2024, the integration was ongoing.Key customers and partnershipPost-merger with Marathon Health, the combined entity would serve 2.5 million patients through over 680 clinics across 41 states.Funding and financialsThe company received its most recent investment in July 2022, amounting to USD 164 million in growth equity funding. The round was led by New Enterprise Associates (NEA). The funds were allocated toward growing its market presence and exploring opportunities for M&amp;A as well as to enhance and improve its product features. Additionally, the firm planned to expand its coverage of specialty care services aimed at individuals, employers, and union organizations.

Everside Health

DPCs offer value-based primary and preventive care services addressing whole-person (social, mental, physical) needs for a fixed monthly or annual fee paid by either the patient, insurance provider, or employer.

Companies offer B2B and D2C evidence-based treatments delivered via software programs to prevent and manage a variety of chronic conditions.

Tools that collect and analyze real-time patient data that supports healthcare providers with clinical decisions,  improves patient outcomes, and reduces medical errors.

Companies offer independent physician practices and hospitals with the tools (patient engagement, care coordination, administrative services) to help manage and improve clinical health outcomes of a defined group of individuals or large populations.

Platforms are used to track and gather patient health-related information via either a connected device or at-home test kits to detect the early onset of disease and identify any abnormalities in readings—but do not include a treatment plan.

To gather large amounts of real-time data for chronic care management, DTx, and patient monitoring

XR used by some startups for chronic pain management

Offers digital means of providing direct primary care, passive remote monitoring, chronic care management, etc.

AI/ML is used in predictive analytics, diagnostics tools, and population management

Offers tailored preventive interventions and treatments to the specific needs and characteristics of each individual

Nice healthcare is a virtual and in-home primary care provider that offers a suite of healthcare services to small and medium-sized businesses, including primary care, mental health therapy, and physical therapy. Nice healthcare operates on a fixed monthly fee per member model, allowing employees to access unlimited care without additional out-of-pocket costs. The company provides virtual consultations through its app, as well as in-home visits for physical exams, lab tests, and X-rays.&nbsp;As of <a href="https://www.nice.healthcare/locations">August 2024</a>, Nice Healthcare was operating in 12 states: Arizona, Colorado, Idaho, Iowa, Minnesota, Nebraska, Nevada, New Mexico, Oregon, Utah, Washington, and Wisconsin. The company's services covered <a href="https://www.nice.healthcare/the-nicessities/three-categories-of-primary-care#:~:text=Only%204%25%20of%20our%20patients,with%20Nice%20may%20look%20like.">over 95%</a> of issues patients typically discuss with their clinicians, with <a href="https://www.nice.healthcare/the-nicessities/three-categories-of-primary-care#:~:text=Only%204%25%20of%20our%20patients,with%20Nice%20may%20look%20like.">only 4%</a> of patients being referred to external specialists. The company employs nurse practitioners, registered nurses, physician assistants, and medical assistants to deliver care.As of <a href="https://www.nice.healthcare/the-nicessities/three-categories-of-primary-care">August 2024</a>, Nice healthcare offered 35 free labs and physical tests as well as in-home imaging services and prescribed over 550 free medications that could be picked up at over 60,000 pharmacies nationwide or delivered to patients' homes.&nbsp;Key customers and partnershipsIn <a href="https://www.prnewswire.com/news-releases/getlabs-and-nice-healthcare-partner-to-expand-access-to-virtual-healthcare-services-and-at-home-lab-testing-301813668.html">May 2023</a>, Nice Healthcare announced a partnership with Getlabs, a provider of at-home diagnostic collections. This collaboration aimed to expand access to in-home healthcare services and lab testing, allowing Nice healthcare patients to benefit from a more comprehensive suite of diagnostic tests.

Nice Healthcare

Amicomed is a cloud-based Software-as-a-Service (SaaS) platform which provides blood pressure monitoring services. It collects blood pressure data of patients from at-home devices, applies algorithms, and assesses the fluctuations in the blood pressure. Physicians can be connected and provided with blood pressure data of their patients in order to facilitate their workload, enabling more personalized management of patients regarding medication and lifestyle indications.Amicomed can also recommend actionable and personalized lifestyle interventions such as daily diet and exercises via virtual coaching.

Amicomed

Winston is a men’s health telemedicine platform that treats common issues impacting men such as sexual problems, hair loss, acne, and cold sores. Winston allows patients to consult doctors, place orders for prescription drugs, and offers free delivery to the homes of patients.The Toronto-based company aims to avoid men deferring doctor visits or withholding sensitive information. The consultation fee is covered by the provincial health plan, but the prescriptions are billed to the customer.

Winston

Dialogue is a leading virtual care and well-being platform that provides comprehensive health services to organizations and their employees. Founded in 2016, the company offers an integrated health platform that centralizes various health and wellness programs in a single application, accessible <a href="https://www.dialogue.co/en/blog/dialogues-2023-year-in-review#:~:text=Serving%2015%25%20of%20the%20Canadian%20population&amp;text=How%3F,aspects%20of%20their%20well%2Dbeing.">24/7/365</a>. Dialogue's services include primary care, mental health support, employee assistance programs, and wellness initiatives. As of <a href="https://www.dialogue.co/en/blog/dialogues-2023-year-in-review#:~:text=Serving%2015%25%20of%20the%20Canadian%20population&amp;text=How%3F,aspects%20of%20their%20well%2Dbeing.">December 2023</a>, Dialogue's platform was accessible to around 6 million Canadians, representing approximately 15% of the country's population.The company saw significant growth in <a href="https://www.dialogue.co/en/blog/dialogues-2023-year-in-review#:~:text=Serving%2015%25%20of%20the%20Canadian%20population&amp;text=How%3F,aspects%20of%20their%20well%2Dbeing.">December 2023</a>, with a 34% increase in consultations across all aspects of well-being in 2023 compared to the previous year. Mental health consultations, in particular, saw a 67% increase.&nbsp;In <a href="https://www.newswire.ca/news-releases/dialogue-enters-into-license-agreement-with-sun-life-u-s--824463104.html">July 2023</a>, Dialogue was acquired by Sun Life for an undisclosed sum, expanding its reach beyond Canada. This expanded service reach was estimated to cover an additional 600,000 members in the US. The acquisition was completed in <a href="https://www.sunlife.com/en/newsroom/news-releases/announcement/sun-life-completes-the-acquisition-of-dialogue-canadas-premier-health-and-wellness-virtual-care-platform/123792/">October 2023</a>, with Dialogue continuing to operate as a standalone entity.Key customers and partnershipsThe company has partnerships with major insurers and benefits providers to offer its services as part of employee benefits packages. Additionally, the company noted that, as of <a href="https://www.dialogue.co/en/pricing">August 2024</a>, it worked with over 50,000 companies across Canada to provide its services to employees.

Dialogue

Grin offers telemedicine and remote monitoring services for orthodontic needs such as braces and teeth straightening. Patients can conduct self-scans (using a Grin device made available to patients in collaboration with 3M) which can be connected to their smartphones and share the feed with orthodontists to access dental solutions. The company plans to go to a subscription-based model after the pandemic. The app also encourages patients to have a 40-second check monthly and share the scan with a dentist in order to allow patients to regularly maintain their dental hygiene.Grin is the only Telehealth disruptor covered on the hub that provides virtual orthopaedic consultations.Funding and financialsIn April 2021, the New York-based teledental platform concluded a seed funding of USD 14 million, and the funds will be allocated to develop additional functionalities by building out its technology. The proceeds will also be used to scale up its team, expand its geographic footprint, and add doctors to the company’s orthodontic partner network.

Grin

Real-time collection of patients’ health-related data using any remote patient monitoring device combined with general telemedicine services to reduce readmission rates.

A platform that facilitates the transmission of patient data to different locations for further evaluation and interpretation by medical specialists.

A digital platform that offers specialty care services to address the specific needs of a patient or demographic, including consultations where patients are generally reluctant to meet practitioners face-to-face.

Primary care through virtual consultations for general health-related concerns using a digital platform or mobile app.

Companies developing B2B software solutions for patient engagement, care navigation, practice management, and electronic health records integration to facilitate telehealth services for healthcare providers.

Companies that use GenAI as a core part of their product offering for Telehealth

IoT is used by most telehealth providers to operate virtual services

All telehealth players are involved in digital health via virtual offerings

Industry players offer varying degrees of personalization for each target audience

Some players offer technology and platforms to healthcare providers, converting physical-only services into virtual services

Specific telehealth offerings focus on diversity and inclusion, providing care to LGBTQ+ or BIPOC populations

Generative AI is used to streamline administrative tasks such as clinical note-taking

ANALYST_QUICK_TAKE

<div>

Digital health platform Glooko has garnered USD 100 million in a Series F funding session led by Georgian. Health Catalyst Capital, Canaan, along with other investors and business partners also participated. With this round, the total funds amassed by the company have reached USD 301 million.

The funds will be channelled towards accelerating the worldwide expansion of Glooko's digital healthcare platform and life sciences ventures. This initiative aims to empower diabetic people to manage their condition more effectively and enhance interaction with their medical teams.

Glooko’s platform is designed to enhance health outcomes for individuals with chronic disorders through customized, smart, and integrated care. As of October 2024, the Glooko platform has been used by over 4.4 million people globally suffering from diabetes.

</div> Analyst QuickTake: 
 Previously, in <a href="https: 
//sp-edge.com/updates/25233"> January 2024 </a> , the company partnered with Better Therapeutics, a prescription digital therapeutic startup to integrate Better Therapeutics' AspyreRx, a digital behavioral treatment for type 2 diabetes (T2D), into Glooko's platform. The company’s focus on entering such partnerships also complements its efforts on global product expansion.

Glooko

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless